



RECEIVED

JUL 17 1995

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et. al.  
Serial No.: 08/087,132  
Filed: July 2, 1993

Examiner: Dr. K. C. Carlson  
Art Unit: 1812  
Docket: NZI-012CN  
IG4-9.2(FWC)

30

For: NEW DIAGNOSTIC AND TREATMENT METHODS  
INVOLVING THE CYSTIC FIBROSIS TRANSMEMBRANE  
REGULATOR

Honorable Commissioner of  
Patents and Trademarks  
Washington, DC 20231

—CERTIFICATE OF MAILING UNDER 37 CFR §§ 1.8—

I hereby certify that this correspondence is being deposited this day  
with the U.S. Postal Service as first class mail, sufficient postage prepaid, in an  
envelope addressed to the Commissioner of Patents and Trademarks,  
Washington, DC 20231.

Date: June 9, 1995 By: Kim Akeeli  
Kim Akeeli

Supplementary Information Disclosure Statement

Pursuant to 37 CFR 1.56, 1.97 and 1.98

SIR:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants respectfully direct the  
Examiner's attention to the following further publications.

1. L. Tsui et al., "Stable Propagation of Modified Full Length Cystic Fibrosis  
Transmembrane Conductance Regulator Protein cDNA in Heterologous  
Systems", International Patent Application Number PCT/CA91/00341 published  
on April 2, 1992, bearing Publication Number WO 92/05252, and claiming the  
priority of Great Britain national application 9020632.7 filed September 21, 1990.

Information Disclosure Statement  
08/087,132  
June 9, 1995  
page 2

2. F.S. Collins et al., "Gene Therapy for Cystic Fibrosis", International Patent Application Number PCT/US91/06660 published on April 2, 1992, bearing Publication Number WO 92/05273, and claiming the priority of United States patent application 07/584,275 filed September 18, 1990.
- 3 M. Drumm et al., "The Full Length CFTR cDNA is Toxic in Bacteria", Pediatric Pulmonology, Supplement 5 (Abstracts), October 1990, Abstract No. 8, page 189.
4. L. Tsui, "Probing the Basic Defect in Cystic Fibrosis", Current Opinion in Genetics and Development, 1, 1991, pp. 4-10.

Copies of the above publications are being included in the **Exhibit Book** that is being filed herewith. Publications 1, 2, 3 and 4 as enumerated above can be found in the Exhibit Book as documents (G), (E), (H), and (J) respectively.

PTO Form 1449 is included herewith. Since this Supplemental Information Disclosure Statement is being submitted after the issuance of a non-final Official Action herein, a Petition with the appropriate fee, 37 CFR 1.17(p), 1.97(c), is included herewith.

Respectfully submitted,

GENZYME CORPORATION

By: William G. Gosz  
~~Mark A. Hofer, Esquire~~  
~~Registration No. 30,068~~ 27,787  
Attorney for Applicants  
William G. Gosz

Dated: 6/9/95

One Mountain Road  
Framingham, MA 01701-9322  
(508) 872-8400